combination

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer

Zolbetuximab plus mFOLFOX6—a chemotherapy combination commonly used in gastric cancer—significantly prolonged patients’ progression-free survival compared with mFOLFOX6 alone in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction ( GEJ) adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial. The results, presented during the 2023 Gastrointestinal Cancer Symposium, a conference organized …

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer Read More »

A novel combination of triple immunotherapy improves antitumor responses in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a poor prognosis and limited treatment options. Researchers at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and the only National Cancer Institute-designated Comprehensive Cancer Center, along with RWJBarnabas Health, in collaboration with researchers at MD Anderson Cancer Center, have discovered a …

A novel combination of triple immunotherapy improves antitumor responses in preclinical models of pancreatic cancer Read More »